Baricitinib
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Baricitinib
- Pharmacist Assessment Report
- Baricitinib: From Rheumatoid Arthritis to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Baricitinib: From Rheumatoid Arthritis to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
One-Sentence Summary
Baricitinib is a drug originally used to treat rheumatoid arthritis. The TxGNN model predicts it may be effective for colobomatous microphthalmia-rhizomelic dysplasia syndrome, an extremely rare developmental disorder. This prediction is supported by 0 clinical trials and 0 publications, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis |
| Predicted New Indication | Colobomatous microphthalmia-rhizomelic dysplasia syndrome |
| TxGNN Prediction Score | 0.9994 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (10 of 10) – CDSCO approval status is not included in this data |
| Number of Listed Products | 10 (valid: 10) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Baricitinib is generally known as a JAK1/JAK2 inhibitor, and its efficacy in rheumatoid arthritis is established. However, this general knowledge is not documented in the compiled data.
No mechanistic link to the predicted disease can be established. Colobomatous microphthalmia-rhizomelic dysplasia syndrome is an extremely rare developmental condition, and the compiled data show no involvement of JAK-STAT signalling. The high score (0.9994) is a computational TxGNN model (deep learning) prediction. It may reflect network proximity artifacts rather than true biological plausibility.
A second prediction, brachydactyly-syndactyly syndrome (score 0.9994), has the same limitations. It is a congenital limb malformation with no supporting trials or literature. A structural developmental disorder is also unlikely to respond to an immunomodulatory drug after birth.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 26846 | Barinat 1 Tablet (Natco Pharma) | Bottle of 14 tablets | Not specified in available data |
| 25844 | Barinat 4 Tablet (Natco Pharma) | Bottle of 14 tablets | Not specified in available data |
| 26323 | Barilup 4mg Tablet (Lupin) | Bottle of 14 tablets | Not specified in available data |
| 161925 | Olumiant 4mg Tablet (Eli Lilly India) | Strip of 7 tablets | Not specified in available data |
| 163438 | Olumiant 2mg Tablet (Eli Lilly India) | Strip of 7 tablets | Not specified in available data |
There are 10 valid single-ingredient registrations in total, all oral tablets.
Safety Considerations
- Drug Interactions: 321 interactions were recorded. Major-level interactions include:
- Corticosteroids: hydrocortisone, triamcinolone (including ophthalmic), betamethasone, budesonide, dexamethasone, prednisolone, prednisone
- Deferiprone
- Radiopharmaceuticals: ibritumomab tiuxetan, iobenguane (I-131), tositumomab (I-131)
- Moderate-level interactions include morphine (including liposomal), opium, acetylsalicylic acid and nitisinone.
- Minor-level interactions include zinc salts (acetate, gluconate, sulfate).
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trial or literature support (Evidence Level L5). No biological link between baricitinib and this ultra-rare developmental syndrome can be established from the available data. The high model score alone is not sufficient to justify moving forward.
To proceed, the following is needed:
- Detailed mechanism of action data and a plausible pathway link to the predicted disease
- Package insert warnings and contraindications from the India market, which are required for safety screening
- Any preclinical or clinical evidence connecting JAK inhibition to this syndrome
- Assessment of route compatibility and similarity to the original indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.